Back to search results

Understanding Survivorship Care for Prostate Cancer

This study is for Black and African American men who have completed treatment for localized or oligometastatic prostate cancer (cancer that has not spread widely). It compares two types of survivorship care plans (SCPs), which are summaries of your treatment history and recommendations for your ongoing health. One group will receive a standard SCP, while the other will receive a tailored SCP along with an educational supplement designed to be easy to understand. Researchers want to see if the tailored plan helps you better understand your care recommendations and prostate specific antigen (PSA) surveillance, as well as the side effects of your treatment. The study aims to enroll 150 participants.

Study design
This is an interventional study with 150 planned participants. Participants will be randomly assigned to one of two groups: one receiving a standard SCP and the other receiving a tailored SCP with an educational supplement.
What's involved
Participants will receive either a standard SCP or a tailored SCP with an educational supplement during a provider visit. They will also undergo a structured interview lasting 30-60 minutes.
Compensation
Not stated in the trial record.
Follow-up
Your comprehension of care recommendations and side effects will be measured at baseline and up to a 3-month phone call.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06674863

Addressing Health Literacy With a Tailored Survivorship Care Plan

Recruiting
NAAges 18+InterventionalSupportive care
Emory University
~150 participants
Updated 2025-12-09 on ClinicalTrials.gov
What's tested:Educational InterventionInterviewQuestionnaire AdministrationSupportive Care

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Comprehension of survivorship care recommendations and prostate specific antigen surveillance
Measured over At baseline and up to 3 month phone call
+1 more outcome measured

Conditions

Localized Prostate Carcinoma
Oligometastatic Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8

Explore related trials

Prostate Carcinoma

Where it's being run

3 sites across 1 states
Georgia3

Study leadership

  • Viraj Master, MD, PhD, FACS · PRINCIPAL_INVESTIGATOR · Emory University Hospital/Winship Cancer Institute

Who to contact

Kerry L. Kilbridge, MD, MSc
[email protected]
617-632-2429
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
Patients who are still receiving adjuvant androgen deprivation therapy following primary radiation with non-palliative intent may be included

Exclusion

Dementia or cognitive impairment per provider clinical assessment
Unable to give informed consent in the judgement of the patient's oncology provider
Recurrent prostate cancer after primary treatment
Less than 18 years of age at the time of informed consent
Diagnosis of active second malignancy requiring treatment
Individuals who are not able to clearly understand English since the outcome measures require understanding of English

What this trial measures

  • Comprehension of survivorship care recommendations and prostate specific antigen surveillanceAt baseline and up to 3 month phone call

    Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard survivorship care plan (SCP) compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P \< 0.05.

  • Comprehension of treatment side effects and late effectsAt baseline and up to 3 month phone call

    Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard SCP compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P \< 0.05.